The shareholders of Straub Medical AG (Switzerland) have sold 100% of the shares to the US-based Becton, Dickinson and Company.
Straub Medical AG develops, produces, and distributes medical devices for the treatment of vascular diseases. Located in Wangs, in the canton of St. Gallen, Switzerland, Straub Medical manufactures high-precision devices for vascular surgeons and interventional specialists in radiology, angiology, and surgery. Their products are utilized in over 50 countries across Africa, Asia, Europe, and South America.
Straub Medical's product lineup includes catheters for efficient thrombectomy of acute occlusions in veins, arteries, and dialysis accesses, offering a safe and rapid technique for treating acute and subacute ischemia of the lower extremities. Their portfolio also features the CAPTUREX® peri-interventional multi-tool, which is particularly effective in preventing acute pulmonary embolism, as well as specialized guidewires made of Nitinol.
Becton, Dickinson and Company (BD) is an American medical technology company that develops, produces, and distributes disposable medical products, device systems, and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employed nearly 42,000 people as of September 30, 2017. BD supplies hospitals, healthcare facilities, life scientists, clinical laboratories, and industry. Listed on the New York Stock Exchange and included in the S&P 500 Index, BD generated sales of more than USD 12 billion in 2017.
BD is one of the world's leading manufacturers of disposable medical products, designed to prevent the spread of infectious diseases and improve treatments for diabetes and eye surgery. The acquisition of Straub Medical expands BD's product portfolio and strengthens its presence in the Swiss market and the broader DACH region.
ConAlliance is a global advisory firm specializing exclusively in healthcare mergers and acquisitions (M&A), with deep expertise in the medical device market, particularly in vascular interventional technologies. This expertise ensures precise analysis and optimal implementation of the strategic and operational aspects of M&A transactions. ConAlliance's knowledge of market needs and regulatory requirements for medical devices facilitates smoother transitions and maximizes synergies. With a strong track record in handling complex cross-border transactions, ConAlliance's presence and networks in Switzerland and the DACH region offer significant advantages in local market knowledge and cultural nuances. This regional footprint enhances communication and negotiations, strengthening BD's position in the European market.
For more information about ConAlliance, please visit www.conalliance.com.